Science Corporation, the ambitious medical technology firm founded by former Neuralink president Max Hodak, has announced a significant milestone in its journey to bridge the gap between human biology and advanced silicon-based interfaces. On November 17, 2026, the company revealed that it has successfully closed a $400 million Series D funding round, a move that signals robust investor confidence in the startup’s long-term vision. According to a person familiar with the details of the transaction, the latest financing round has pushed the company’s valuation to an impressive $3.5 billion. This infusion of capital brings together a consortium of high-profile backers, including Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. The support from such a diverse array of institutional and strategic investors underscores the growing interest in the intersection of neuroscience, biotechnology, and silicon engineering. Read Also: Beyond the Hype: Decoding What It Takes to Build an Enduring AI Giant Turning Abandoned Oil Wells into Clean Hydrogen Generators: A New Frontier for Energy Founded in 2021, Science Corporation was born from Max Hodak’s desire to push the boundaries of how we understand and interact with the human brain. Hodak, who built a reputation for deep curiosity and technical ambition—notably by talking his way into a graduate-level neuroscience lab while still an undergraduate—has spent his career focused on the practical application of biotechnology. His departure from Neuralink to establish Science Corporation marked a strategic pivot toward a more holistic, and arguably more cautious, approach to neural integration. Bringing Vision to the Blind: The PRIMA System While the company’s long-term roadmap is deeply rooted in direct brain-computer interfaces, its immediate impact is being felt through its flagship product, PRIMA. The device is a sophisticated blend of wearable technology and a sub-retinal implant designed to restore vision in patients suffering from age-related macular degeneration (AMD). The PRIMA system works by providing a visual prosthetic that helps patients recover a degree of functional sight. Its clinical success has already been validated in Europe, where the device is currently approved and available for use in Germany. This success serves as both a proof-of-concept for the company’s engineering prowess and a revenue-generating anchor that allows the firm to fund its more speculative research and development projects. The potential for the technology to assist those with degenerative eye conditions continues to expand. At the recent TechCrunch Disrupt conference, Hodak announced that the PRIMA system is being actively trialed for patients suffering from Stargardt disease, a genetic, inherited disorder that causes progressive vision loss in children and young adults. By applying the same underlying technology to different pathologies, Science Corporation is demonstrating the versatility of its visual restoration platform. Expanding into the U.S. Market With the newly secured $400 million in funding, Science Corporation is turning its focus toward the United States market. The regulatory landscape for medical devices is notoriously complex, but the company is pursuing a strategic pathway through the FDA’s Humanitarian Device Exemption (HDE). The HDE program is specifically designed to incentivize the development of devices intended to treat or diagnose diseases or conditions that affect a small population—fewer than 8,000 individuals in the U.S. per year. Science Corporation has made a compelling case to federal regulators that advanced macular degeneration, when affecting both eyes, falls under the criteria necessary to qualify for this designation. Securing this exemption would provide a critical, accelerated route to bringing the PRIMA technology to American patients who currently have few, if any, effective treatment options. The Future of Neural Integration Beyond the immediate success of its vision-restoration efforts, Science Corporation remains committed to its original, foundational ambition: creating a seamless, bio-hybrid connection to the human brain. This is the "North Star" of the company, and it represents a massive technical leap beyond current ocular implants. The company is developing a proprietary bio-hybrid sensor that functions by integrating cultured neurons with silicon circuitry. The objective is to create a more natural interface that can record and potentially stimulate neural activity with a level of precision and biocompatibility that rigid, traditional implants struggle to achieve. This development is being led in collaboration with leading figures in the field, most notably Yale neurosurgery professor Murat Günel. The partnership is a cornerstone of the company’s research strategy. Dr. Günel, a prominent voice in the neurosurgical community, has been instrumental in preparing the framework for the company’s upcoming human clinical trials. The implications of such a device, if proven safe and effective, are profound. The research team is currently focused on exploring how these sensors might offer new, life-changing treatment pathways for patients suffering from Parkinson’s disease. Given the chronic and debilitating nature of Parkinson’s, the ability to directly interface with the brain to modulate neural activity could represent a revolutionary shift in the standard of care for neurodegenerative disorders. Beyond Parkinson’s, the potential applications for this technology are broad, extending to various brain injuries and complex neurological illnesses that have historically been resistant to pharmacological intervention. By successfully placing its first sensor in a human brain, Science Corporation aims to move from the realm of theoretical neuroscience into the clinical reality of restorative medicine. A New Chapter for Biotech The $400 million Series D is more than just a financial milestone; it is a validation of the niche Science Corporation has carved out for itself. In an industry often dominated by high-speed, high-risk endeavors, the company has managed to balance the delivery of near-term medical solutions with the pursuit of long-term, paradigm-shifting science. As the company prepares to navigate the FDA approval process for the PRIMA system and simultaneously advances its brain-sensor research, the eyes of the biotech and investment worlds remain fixed on its progress. For Max Hodak and his team, the challenge lies in maintaining the delicate balance between the regulatory rigors of the medical device industry and the high-innovation pace required to redefine the future of human-machine interaction. With a strong balance sheet and a clear clinical pipeline, Science Corporation enters this new phase of growth with significant momentum. The coming years will be critical as the company transitions from a startup with a vision to an established player in the medical technology market, potentially changing the lives of thousands of patients in the process. Through its methodical approach to both the eye and the brain, Science Corporation is positioning itself as a vital architect of the future of human health. Post navigation Hank Green Launches ClockwiseTV to Combat Infinite Scrolling and Digital Fatigue in Children